Mural Oncology Plc (MURA) - News Archive

Mural Oncology: A Gamble in the High-Stakes Game of Immuno-OncologyIn the ever-evolving landscape of cancer treatment, Mural Oncology Plc stands at a precipice of promise and peril. The clinical-stage biotech firm, wadi...

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)In a strategic move reflecting its commitment to both innovation and talent acquisition, Mural Oncology plc (Nasdaq: MURA), a clinical-stage c...

In a significant contribution to the field of oncology, Mural Oncology recently announced the publication of remarkable findings from its ARTISTRY-1 clinical trial, which investigates the therapeutic potential of its le...

Mural Oncology Plc recently announced its third quarter 2024 financial results alongside an update on its pipeline progress, attracting the attention of investors and industry analysts. While the company s shares have u...

Immunotherapy has emerged as a promising cornerstone in the fight against cancer, showcasing substantial advances in patient outcomes. At the recent 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC),...

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)On November 4, 2024, Mural Oncology plc, a clinical-stage immuno-oncology firm headquartered in Waltham, Massachusetts, and Dublin, made a sig...

In a noteworthy development on October 1, 2024, Mural Oncology plc (Nasdaq: MURA), a pioneering clinical-stage company in the field of immuno-oncology based out of Waltham, Massachusetts, and Dublin, made significant st...

Mural Oncology s recent announcement regarding its first virtual investor day has drawn attention to the company s late-stage clinical trials involving nemvaleukin, a novel therapeutic targeted at specific cancer types....

WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 - Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company dedicated to developing groundbreaking engineered cytokine therapies, announced on August 1 that it...

In recent news, Mural Oncology plc (Nasdaq: MURA) announced the granting of non-statutory stock options and restricted stock units to newly hired employees as part of the company s 2024 Inducement Stock Option and Incen...

In recent years, the field of immuno-oncology has witnessed groundbreaking advancements that offer new hope for cancer patients. Mural Oncology, a leading clinical-stage immuno-oncology company, has been at the forefron...

Mural Oncology plc, a clinical-stage immuno-oncology company, announced the granting of non-statutory stock options and restricted stock units to three newly hired employees. These inducement grants have been made by th...

:An industry leader in immuno-oncology, Mural Oncology, has recently announced strategic modifications to late-stage clinical trials, ARTISTRY-6 and ARTISTRY-7, and has presented remarkable preclinical data concerning i...

Mural Oncology, a pioneering immuno-oncology firm specializing in immune cell modulation and protein engineering, recently made an important announcement regarding their new hires. The company has granted non-statutory...

Mural Oncology plc (Nasdaq: MURA), a leading clinical-stage immuno-oncology company, made a significant announcement today regarding its fourth quarter and year-end financial results for 2023. The company s strong perfo...

Mural Oncology Grants Inducement Options and Restricted Stock Units to Newly Hired EmployeesDUBLIN, Ireland March 04, 2024 - Mural Oncology plc (Nasdaq: MURA), a renowned clinical-stage immuno-oncology company specializ...

Mural Oncology Revolutionizes Late-Stage Clinical Trials: Maximizing Clinical Relevance with ARTISTRY-6 and ARTISTRY-7 In a groundbreaking development, Mural Oncology has unveiled strategic enhancements to their late-st...